AbbVie says global Humira market eroding faster than expected

AbbVie Inc. (NYSE:ABBV) Chairman and CEO Richard Gonzalez said the company now expects greater erosion in ex-U.S. sales of autoimmune drug Humira adalimumab by the end

Read the full 268 word article

User Sign In